New drug ORIC-944 targets Hard-to-Treat prostate cancer

NCT ID NCT05413421

Recruiting now Disease control Sponsor: ORIC Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This trial investigates a new oral drug called ORIC-944, given alone or combined with standard hormone therapies, for men with metastatic prostate cancer that has spread beyond the prostate. The study aims to find the safest dose and check for early signs that the drug can control the cancer. Participants must have already tried at least one hormone therapy and may have had chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ORIC-944
What this could lead to: If successful, ORIC-944 could offer a new treatment option for men with metastatic prostate cancer that has stopped responding to current hormone therapies.
What could go wrong: This is an early-phase trial focused on safety and dosing, so it is not yet known if ORIC-944 will effectively shrink tumors or improve survival. Side effects are still being identified.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Amarillo Urology Research
RECRUITING

Amarillo, Texas, 74035, United States
Bendigo Health
RECRUITING

Bendigo, Victoria, Australia
Comprehensive Urologic Care
RECRUITING

Lake Barrington, Illinois, 60010, United States
First Urology
RECRUITING

Jeffersonville, Indiana, 47130, United States
Huntsman Cancer Institute, University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States
Illinois Cancer Specialists
RECRUITING

Arlington Heights, Illinois, 60005, United States
Karmanos
RECRUITING

Detroit, Michigan, 48201, United States
Keystone Urology Specialists
RECRUITING

Lancaster, Pennsylvania, 17601, United States
Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States
Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland
RECRUITING

Baltimore, Maryland, 21201, United States
Maryland Oncology Hematology
RECRUITING

Silver Spring, Maryland, 20904, United States
Memorial Sloane Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
MidLantic Urology
NOT_YET_RECRUITING

Bala-Cynwyd, Pennsylvania, 19004, United States
Minnesota Oncology Hematology
RECRUITING

Minneapolis, Minnesota, 55404, United States
NEXT Oncology
RECRUITING

Barcelona, Barcelona, Spain
NEXT Oncology
RECRUITING

Madrid, Spain
Peninsula Health
NOT_YET_RECRUITING

Frankston, Victoria, Australia
Rocky Mountain Cancer Center
RECRUITING

Colorado Springs, Colorado, 80907, United States
Royal Marsden NHS Foundation Trust
RECRUITING

Sutton, Surrey, United Kingdom
South Florida Oncology and Hematology
RECRUITING

Plantation, Florida, 33322, United States
Sydney Adventist Health
RECRUITING

Wahroonga, New South Wales, Australia
University of Washington, Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
University of Wisconsin Carbone Cancer Center
NOT_YET_RECRUITING

Madison, Wisconsin, 53792, United States
Urology Clinics of North Texas
RECRUITING

Dallas, Texas, 75231, United States
Vall d'Hebron Institute of Oncology
RECRUITING

Barcelona, Barcelona, Spain
Virginia Cancer Specialists
NOT_YET_RECRUITING

Norfolk, Virginia, 23502, United States
Virginia Oncology Associates
RECRUITING

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.